BRAF and melanoma: Since BRAF and NRAS mutations are mutually exclusive in nearly all cases (52, 53), it is widely recognized that about two-thirds of patients present a melanoma with activation of the MAPK pathway, carrying a mutated BRAF or NRAS gene.